Evidence map›Paper›PMID 41355961›Full record

ArticleTheranostics2026

Prognostic implications of [¹⁸F]FDG PET and metabolic changes in patients with advanced metastatic neuroendocrine tumors undergoing rechallenge PRRT: final results from a multicenter 10-year survival WARMTH study.

Giulia Santo, Margarida Rodrigues, Diana Paez, Olga Morozova, Levent Kabasakal, Kalevi Kairemo, Chiara Maria Grana, Richard P Baum, Gianpaolo di Santo, Irene J Virgolini

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Giulia SantoDepartment of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Margarida RodriguesDepartment of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Diana PaezNuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency (IAEA), Vienna, Austria.
Olga MorozovaNuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency (IAEA), Vienna, Austria.
Levent KabasakalDepartment of Nuclear Medicine, İstanbul University-Cerrahpasa Medical Faculty, İstanbul, Türkiye.
Kalevi KairemoNuclear Medicine and Theragnostics, Docrates Cancer Center, Helsinki, Finland.
Chiara Maria GranaRadiometabolic Therapy Unit, Division of Nuclear Medicine, IRCCS IEO European Institute of Oncology, Milano, Italy.
Richard P BaumMolecular Radiotherapy, Curanosticum Wiesbaden-Frankfurt, Germany.
Gianpaolo di SantoDepartment of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Irene J VirgoliniDepartment of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Fluorodeoxyglucose F18Neuroendocrine TumorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm MetastasisPositron-Emission TomographyPositron Emission Tomography Computed TomographyPrognosisRadiopharmaceuticalsReceptors, PeptideRetrospective StudiesFluorodeoxyglucose F18RadiopharmaceuticalsReceptors, Peptide[18F]FDG PETneuroendocrine tumorspeptide receptor radionuclide therapyprognosisrechallenge

Identifiers

PMID41355961
PMCPMC12679270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.